#Israel #Rehovot #Evogene #ChemPass AI #Ofer Haviv

Evogene's New Path to Sustainable Growth

Overview of Recent Developments

On February 25, 2026, Evogene Ltd., publicly traded on Nasdaq under the symbol EVGN, released a comprehensive letter from its President and CEO, Ofer Haviv. This communication serves to update shareholders on the major advancements and strategic realignment the company has undertaken over the past year.

Founded in Rehovot, Israel, Evogene has carved out a niche as a pioneering computational chemistry firm specializing in generative AI designs for small molecules. These innovations primarily target the pharmaceutical and agricultural sectors, reflecting a commitment to harnessing technology for real-world impact.

Sharpening Focus on Core Technologies

Throughout 2025, Evogene initiated a thorough analysis of its technology, market positioning, and allocation of capital. This review highlighted the necessity to consolidate efforts and maximize efficiency, leading to two pivotal strategic decisions focused on long-term value creation.

1. Consolidation of Technology Development: The company has chosen to concentrate its technological resources on a single computational platform, ChemPass AI™. This proprietary engine is designed to enhance the discovery and optimization of small molecules crucial to therapeutics in human health and innovative agri-chemicals.

2. Streamlining Business Operations: Evogene has narrowed down its business activities, centering exclusively around two high-impact markets: human health and agriculture. This shift towards specialization has allowed Evogene to allocate resources and energy toward initiatives that promise substantial returns, thereby reinforcing the company’s overall agility and efficiency.

Advancements Through ChemPass AI™

ChemPass AI™ stands out due to its ability to generate novel, highly active small molecules while adhering to complex parameters essential for successful drug development. The platform is backed by advanced technology developed by Evogene’s dedicated internal team and is complemented by collaborations with industry titans, including Google Cloud. This partnership marks the beginning of a second collaborative project, showcasing ChemPass AI™ as a cornerstone of Evogene's innovation strategy.

Unique Market Positioning and Competitive Edge

ChemPass AI™ distinguishes itself by navigating expansive chemical territories that others in the industry may overlook. With a foundation model based on a calculation of 38 billion different molecules, Evogene is positioned to develop original molecular structures that exhibit significant biological activity alongside robust intellectual property rights.

Moreover, precision is paramount in their design process. Each molecule is engineered to meet the distinctive needs of target products from conception to within predefined success parameters, effectively increasing the likelihood of market success significantly.

Business Model and Immediate Goals

The company's business model is strategically flexible and capital-efficient and encompasses partnerships focused on specific outcomes alongside internally initiated programs. In the realm of human health, Evogene is actively working on several partnered drug discovery initiatives with biotechnology firms and academic institutions, anticipating an expansion of collaborative efforts as additional programs progress into testing phases.

In agriculture, Evogene’s subsidiary, AgPlenus, leverages ChemPass AI™ for the advancement of innovative herbicides and fungicides. The operational maturity of this platform is underscored by successful partnerships with industry leaders such as Bayer and Corteva, indicating a robust internal pipeline that foreshadows continued growth.

Strategic Divestments and Future Aspirations

In addition to focusing on high-value opportunities, the company has effectively divested from non-core subsidiaries, including the acquisition of Lavie Bio's activities by ICL, and the licensing of Biomica's leading oncology candidate to Lishan Pharmaceuticals. Such strategic moves reflect Evogene's commitment to retaining a selective number of assets with substantial value potential, like Casterra.

The concerted efforts to enhance ChemPass AI™, coupled with disciplined financial management and strategic alliances, ensure that Evogene is well-positioned for sustainable growth and long-term shareholder value.

Conclusion

As Evogene embarks on this refined path toward innovation and value creation, shareholder confidence remains paramount. Ofer Haviv’s letter conveys a strong message of commitment and optimism about the future trajectory of the company.

Evogene stands at the forefront of a pivotal transformation, propelling itself into a future where computational chemistry not only meets but exceeds the growing demands of the pharmaceutical and agricultural sectors.

For further insights, visit Evogene's Official Website.